Írsko - angličtina - HPRA (Health Products Regulatory Authority)

fresenius kabi limited - docetaxel anhydrous - concentrate for soln for inf - 80 10 milligram

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

seacross pharmaceuticals - docetaxel anhydrous - concentrate for soln for inf - 80 10 milligram

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

fresenius kabi limited - docetaxel anhydrous - concentrate for soln for inf - 80 10 milligram

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

fresenius kabi limited - docetaxel anhydrous - concentrate for soln for inf - 20 mg/ml

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

vetoquinol uk limited - cloprostenol - solution for injection - 0.250 milligram(s)/millilitre - cloprostenol - cattle - hormone

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - paclitaxel, quantity: 300 mg - injection, concentrated - excipient ingredients: ethanol; citric acid; peg-35 castor oil - primary treatment of ovarian cancer in combination with a platinum agent. treatment of metastatic carcinoma of the ovary after failure of standard therapy. treatment of metastatic carcinoma of the breast after failure of standard therapy. adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin and cyclophosphamide. treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metastatic disease. in combination with gemcitabine (gemzar), the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. treatment of non-small cell lung cancer (nsclc).

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - paclitaxel, quantity: 100.2 mg - injection, concentrated - excipient ingredients: ethanol; peg-35 castor oil; citric acid - primary treatment of ovarian cancer in combination with a platinum agent. treatment of metastatic carcinoma of the ovary after failure of standard therapy. treatment of metastatic carcinoma of the breast after failure of standard therapy. adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin and cyclophosphamide. treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metastatic disease. in combination with gemcitabine (gemzar), the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. treatment of non-small cell lung cancer (nsclc).

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - paclitaxel, quantity: 30 mg - injection, concentrated - excipient ingredients: peg-35 castor oil; citric acid; ethanol - primary treatment of ovarian cancer in combination with a platinum agent. treatment of metastatic carcinoma of the ovary after failure of standard therapy. treatment of metastatic carcinoma of the breast after failure of standard therapy. adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin and cyclophosphamide. treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metastatic disease. in combination with gemcitabine (gemzar), the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. treatment of non-small cell lung cancer (nsclc).

Spojené štáty - angličtina - NLM (National Library of Medicine)

exela pharma sciences, llc - caffeine citrate (unii: u26eo4675q) (caffeine - unii:3g6a5w338e) - caffeine citrate 20 mg in 1 ml - caffeine citrate injection and caffeine citrate oral solution are indicated for the short term treatment of apnea of prematurity in infants between 28 and <33 weeks gestational age. caffeine citrate injection and caffeine citrate oral solution are contraindicated in patients who have demonstrated hypersensitivity to any of its components. this leaflet tells you about caffeine citrate oral solution and how to give it to your baby. read the following information before giving this medicine to your baby. completely discuss caffeine citrate with your baby’s doctor. continue to discuss any questions you have about this medicine at your baby’s checkups. after you remove your baby’s dose, throw away the open bottle (vial) and all medicine left in it. use each vial of caffeine citrate oral solution for only one dose. there will be extra medicine left in the vial after one dose is removed. leftover medicine should not be used because caffeine citrate oral solution does not contain preservatives. once the vial is open

Spojené štáty - angličtina - NLM (National Library of Medicine)

exela pharma sciences, llc - caffeine citrate (unii: u26eo4675q) (caffeine - unii:3g6a5w338e) - caffeine citrate 20 mg in 1 ml - caffeine citrate injection and caffeine citrate oral solution are indicated for the short term treatment of apnea of prematurity in infants between 28 and <33 weeks gestational age. caffeine citrate injection and caffeine citrate oral solution are contraindicated in patients who have demonstrated hypersensitivity to any of its components.